CA3227139A1 - Methods for inhibiting the progression of oxidative retinal diseases - Google Patents
Methods for inhibiting the progression of oxidative retinal diseases Download PDFInfo
- Publication number
- CA3227139A1 CA3227139A1 CA3227139A CA3227139A CA3227139A1 CA 3227139 A1 CA3227139 A1 CA 3227139A1 CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A CA3227139 A CA 3227139A CA 3227139 A1 CA3227139 A1 CA 3227139A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- patient
- progression
- ester
- rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163224690P | 2021-07-22 | 2021-07-22 | |
| US202163224679P | 2021-07-22 | 2021-07-22 | |
| US202163224674P | 2021-07-22 | 2021-07-22 | |
| US63/224,679 | 2021-07-22 | ||
| US63/224,690 | 2021-07-22 | ||
| US63/224,674 | 2021-07-22 | ||
| PCT/US2022/038072 WO2023004151A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3227139A1 true CA3227139A1 (en) | 2023-01-26 |
Family
ID=84979648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3227139A Pending CA3227139A1 (en) | 2021-07-22 | 2022-07-22 | Methods for inhibiting the progression of oxidative retinal diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250099415A1 (https=) |
| EP (1) | EP4373479A4 (https=) |
| JP (1) | JP2024526939A (https=) |
| KR (1) | KR20240036651A (https=) |
| AU (1) | AU2022313207A1 (https=) |
| CA (1) | CA3227139A1 (https=) |
| IL (1) | IL310210A (https=) |
| WO (1) | WO2023004151A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024049497A1 (en) * | 2022-09-02 | 2024-03-07 | Biojiva Llc | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060270739A1 (en) * | 2005-04-28 | 2006-11-30 | Trustees Of Tufts College | Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation |
| CA2723139A1 (en) * | 2007-07-30 | 2009-02-05 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| WO2009058815A2 (en) * | 2007-10-29 | 2009-05-07 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lipoxin a4 protection for retinal cells |
| EP3689342A1 (en) * | 2011-04-26 | 2020-08-05 | Retrotope, Inc. | Oxidative retinal diseases |
| CA3005983A1 (en) * | 2015-11-23 | 2017-06-01 | Retrotope, Inc. | Site-specific isotopic labeling of 1,4-diene systems |
| CA3117216A1 (en) * | 2018-11-15 | 2020-05-22 | Retrotope, Inc. | Deuterated compounds, compositions, and uses |
-
2022
- 2022-07-22 JP JP2024503840A patent/JP2024526939A/ja active Pending
- 2022-07-22 IL IL310210A patent/IL310210A/en unknown
- 2022-07-22 CA CA3227139A patent/CA3227139A1/en active Pending
- 2022-07-22 US US18/291,016 patent/US20250099415A1/en active Pending
- 2022-07-22 EP EP22846695.9A patent/EP4373479A4/en active Pending
- 2022-07-22 KR KR1020247005941A patent/KR20240036651A/ko active Pending
- 2022-07-22 AU AU2022313207A patent/AU2022313207A1/en active Pending
- 2022-07-22 WO PCT/US2022/038072 patent/WO2023004151A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4373479A4 (en) | 2025-11-05 |
| EP4373479A1 (en) | 2024-05-29 |
| KR20240036651A (ko) | 2024-03-20 |
| US20250099415A1 (en) | 2025-03-27 |
| IL310210A (en) | 2024-03-01 |
| AU2022313207A1 (en) | 2024-02-29 |
| WO2023004151A1 (en) | 2023-01-26 |
| JP2024526939A (ja) | 2024-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3735963B1 (en) | Self-emulsifying composition of omega-3 fatty acid | |
| EP3023099B1 (en) | Self-emulsifying composition of -3 fatty acid | |
| RU2709612C2 (ru) | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ | |
| US5834032A (en) | Compositions and methods for treating diabetes | |
| EP3248599A1 (en) | Omega-3 fatty acid self-emulsifying composition | |
| UA76108C2 (en) | Use of therapeutic combination of fatty acids | |
| US11351143B1 (en) | Methods of treating amyotrophic lateral sclerosis | |
| WO2003072111A2 (en) | Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression | |
| BRPI0619598A2 (pt) | composição de emulsão intravenosa de ácido graxo essencial e métodos de administração da mesma | |
| CA3227139A1 (en) | Methods for inhibiting the progression of oxidative retinal diseases | |
| JP4212272B2 (ja) | トリグリセリド低下剤組成物 | |
| US20230255917A1 (en) | Methods of treating amyotrophic lateral sclerosis | |
| KR20180010181A (ko) | Apo c3 의 저하를 위한 티아 옥소 화합물의 용도 | |
| CN118019529A (zh) | 抑制氧化性视网膜疾病进展的方法 | |
| US20240091187A1 (en) | Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof | |
| JP2025507361A (ja) | 網膜酸化的疾患の治療に対する患者の反応をモニタリングする方法 | |
| KR20260010331A (ko) | L-세린의 리포좀 제형 및 이의 제조 방법 | |
| CA3210773A1 (en) | Dosing protocols for administering deuterated arachidonic acid or a prodrug thereof | |
| JP2025506208A (ja) | Ａｌｓ治療のための相乗的併用療法 | |
| JP2020503388A (ja) | 悪液質を予防及び／又は処置するためのオメガ−３脂肪酸組成物 | |
| JPS6011422A (ja) | 抗筋ジストロフイ−症剤 | |
| JPH05139966A (ja) | 月経困難症予防または治療剤と月経困難症予防機能性食品 | |
| JPS6011421A (ja) | 血中脂質降下剤 | |
| EA046793B1 (ru) | Применение композиции (варианты) для профилактического или терапевтического лечения кальцификации сосудов | |
| BR102015007435A2 (pt) | uso de compostos tia oxo para diminuir apo c3 |